Skip to main content

Market Overview

SoftBank To Invest $900M In Pacific Biosciences - WSJ

SoftBank To Invest $900M In Pacific Biosciences - WSJ
  • SoftBank Group Corp (OTCMKTS: SFTBY) will reportedly invest $900 million into Pacific Biosciences of California Inc (NASDAQ: PACB), according to the Wall Street Journal, which comes on top of around 6% stake in PacBio that Softbank amassed almost a month back, worth over $350 million.
  • Last year, PACB was blocked by U.S. antitrust enforcers from merging with Illumina in a $1.2B deal. Illumina paid PacBio a $98 million breakup fee. But under their arrangement, if PacBio raised more than $100 million subsequently, it would owe Illumina $52 million. PacBio will now have to pay that amount.
  • The company recently announced a multi-year collaboration with Invitae Corp (NYSE: NVTA) to begin developing a production-scale high-throughput sequencing platform leveraging PacBio’s HiFi sequencing to expand Invitae’s whole genome testing capabilities.
  • Both companies committed resources to support the development.
  • Price Action: PACB gained 4.45% at $41.3 in premarket trading on the last check Wednesday, while NVTA closed 3.5% higher at $52.6 on Tuesday.
  • Image Courtesy: Wikimedia

Related Articles (SFTBF + SFTBY)

View Comments and Join the Discussion!

Posted-In: Biotech M&A News Offerings Top Stories Tech General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at